Background: We developed a risk score system to predict risks of developing dementia in individual Parkinson disease (PD) patients using baseline neuropsychological tests.
Methods: A total of 216 nondemented PD patients underwent a baseline neuropsychological evaluation and were followed up for a mean of 2.7 (±1.1) years. Univariate Cox regression models controlled for age, gender, and education selected neuropsychological tests individually predicting dementia risk. Then, a multivariate Cox regression model combined them into a cognitive risk score system. Cortical areas correlating with cognitive risk score were investigated using a separate MRI data set from 207 nondemented PD patients.
Results: Fifty-two patients (23.9%) developed dementia. The univariate Cox regression analyses identified the confrontational naming and semantic fluency tests, frontal/executive function tests, immediate verbal memory test, and visuospatial function test as predicting dementia risk. The calculated cognitive risk score (range 53-188) predicted future dementia with moderate accuracy (integrated area under the curve = 0.79; 95% CI: 0.73-0.85). A higher cognitive risk score correlated with cortical thinning in the right anteromedial temporal cortex, bilateral posterior cingulate cortex, right anterior cingulate cortex, left parahippocampal gyrus, and right superior frontal cortex in a separate MRI data set.
Conclusion: The cognitive risk score system is a useful approach to predict the dementia risk among PD patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000479057 | DOI Listing |
J Neuropsychol
January 2025
Department of Health, Medical and Neuropsychology, Leiden University, Leiden, The Netherlands.
Up to 45% of patients with Parkinson's disease (PD) experience impulse control disorders (ICDs), characterized by a loss of voluntary control over impulses, drives or temptations. This study aimed to investigate whether previously identified genetic and psychiatric risk factors interact towards the development of ICDs in PD. A total of 278 de novo PD patients (ICD-free at enrollment) were selected from the Parkinson's Progression Markers Initiative database.
View Article and Find Full Text PDFJ Exp Clin Cancer Res
January 2025
Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a second-line treatment with curative potential for leukemia patients. However, the prognosis of allo-HSCT patients with disease relapse or graft-versus-host disease (GvHD) is poor. CD4 or CD8 conventional T (Tconv) cells are critically involved in mediating anti-leukemic immune responses to prevent relapse and detrimental GvHD.
View Article and Find Full Text PDFBMC Med
January 2025
Department of Public Health Sciences, Stockholm University, Stockholm, Sweden.
Background: Many studies have found more severe COVID-19 outcomes in migrants and ethnic minorities throughout the COVID-19 pandemic, while recent evidence also suggests higher risk of longer-term consequences. We studied the risk of a long COVID diagnosis among adult residents in Sweden, dependent on country of birth and accounting for known risk factors for long COVID.
Methods: We used linked Swedish administrative registers between March 1, 2020 and April 1, 2023, to estimate the risk of a long COVID diagnosis in the adult population that had a confirmed COVID-19 infection.
BMC Med
January 2025
Public Health Foundation of India, House No. 60, 4th Floor, Lane 2, Part of Saidulajab Extension, Near Saket Metro Station Gate No. 2, New Delhi, 110030, India.
Background: India's large youth population presents a significant opportunity to harness the demographic dividend. The disease burden in adolescents could be a hindrance for the future economy if not appropriately addressed.
Methods: We utilised the data on the number of adolescent deaths and attributable years lived with disability (morbidity) in every state of India as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021.
J Anesth Analg Crit Care
January 2025
Department of Anesthesia and Intensive Care, Agostino Gemelli IRCCS University Polyclinic Foundation, Rome, Italy.
Background: Neuromuscular blocking agents (NMBAs) are routinely used in anesthesia practice. An undetected, incomplete recovery of neuromuscular function at the end of surgery potentially exposes patients to clinical deterioration in the postoperative period. The aim of this study was to investigate the incidence of postoperative residual neuromuscular blockade (RNMB) in a cohort of patients receiving NMBAs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!